Abstract:10567 Background: Tumor glucose metabolism correlates with tumor biology and clinical outcome of breast cancer patients. This prospective cohort study was to explore correlations of 18F-FDG uptake, a surrogate for glucose metabolism, with molecular subtypes in women with advanced breast cancer. Methods: Patients diagnosed as advanced breast cancer were enrolled in the study. PET/CT was performed and the Maximum Standardized Uptake Value (SUVmax) of each lesion was documented as baseline, so was clinical and treatment information. Diagnosis of malignant nature of a lesion was confirmed by pathology or further follow-up. Patients who had got a progressive disease in the efficacy assessment were assigned new treatments as per-institutional guidelines. Results: 244 patients met the criteria and were all put into this analysis. Independent factors for influencing SUVmax value included luminal subtype (p= 0.002), triple-negative subtype (p<0.001), ER status (p= 0.028), Her-2 status (p<0.001), and CEA level (p<0.001). A higher SUVmax was significantly associated with poorer median PFS (6.9 vs. 8.1 months, p=0.040) and OS (13.8 vs. 16.9 months, p=0.003). Cox Regression analysis showed that SUVmax value, previous treatments, subsequent treatments and treatment efficacy were four independent prognostic factors for PFS, while age, menopausal status, disease free interval, 4 subtypes, previous treatments, number of metastatic sites, SUVmax value and subsequent treatment efficacy were independent prognostic factors for OS. Conclusions: 18F-FDG uptake correlates with molecular subtypes in women with advanced breast cancer. Baseline SUVmax is an independent prognostic factor for survival of patients with advanced breast cancer, especially those with luminal subtypes.

Correlation of the Maximum Standardized Uptake Value for F-18 Fluorodeoxyglucose with Molecular Subtype and Survival in Advanced Breast Cancer.